Alzheimer Disease (AD) is a neurodegenerative disorder affecting more than 13% of individuals aged 65 years and older and 30%--50% aged 80 years and older^[@R4]--[@R5]^. Early work identified mutations in *APP, PSEN1*, and *PSEN2* that cause early-onset autosomal dominant AD^[@R6]--[@R9]^ and variants in *APOE* that affect LOAD susceptibility^[@R10]^. A recent GWAS identified *CR1, CLU, PICALM*, and *BIN1* as LOAD susceptibility loci^[@R1]--[@R3]^. However, because LOAD heritability estimates are high (*h*^2^ ≈ 60--80%)^[@R11]^, much of the genetic contribution remains unknown.

To identify genetic variants associated with risk for AD, the ADGC assembled a discovery dataset \[Stage 1; 8,309 LOAD cases, 7,366 cognitively normal controls (CNEs)\] using data from eight cohorts and a ninth newly assembled cohort from the 29 NIA-funded Alzheimer Disease Centers (ADCs) ([Supplementary Tables 1 and 2, Supplementary Note](#SD1){ref-type="supplementary-material"}) with data coordinated by the National Alzheimer Coordinating Center (NACC) and samples coordinated by the National Cell Repository for Alzheimer Disease (NCRAD). For the Stage 2 replication, we used four additional datasets and additional samples from the ADCs (3,531 LOAD cases, 3,565 CNEs). The Stage 3 replication used the results of association analyses provided by three other consortia (Hollingworth *et al.*^[@R12]^; 7,650 LOAD cases, 25,839 mixed-age controls). For Stages 1 and 2, we used both a *meta*-analysis (*M*) approach that integrates results from association analyses of individual datasets; and a joint analysis (*J*) approach where genotype data from each study are pooled. The latter method has improved power over *meta*-analysis in the absence of between-study heterogeneity^[@R13]^ and more direct correction for confounding sampling bias^[@R14]^. We were limited to *meta*-analysis for Stage 3.

Because cohorts were genotyped using different platforms, we used imputation to generate a common set of 2,324,889 SNPs. We applied uniform stringent quality control measures to all datasets to remove low-quality and redundant samples and problematic SNPs ([Supplementary Tables 3, 4](#SD1){ref-type="supplementary-material"}, and [Online Methods](#SD5){ref-type="supplementary-material"}). We performed association analysis assuming an additive model on the log odds ratio scale with adjustment for population substructure using logistic regression for case-control data and generalized estimating equations (GEE) with a logistic model for family data. Results from individual datasets were combined in the *meta*-analysis using the inverse variance method, applying a genomic control to each dataset. The joint analysis was performed using GEE and incorporated terms to adjust for population substructure and site-specific effects ([Online Methods](#SD5){ref-type="supplementary-material"}). For both approaches, we also examined an extended model of covariate adjustment that adjusted for age (age at onset or death in cases; age at exam or death in controls), sex, and number of *APOE* ε4 alleles (0, 1, or 2). Genomic inflation factors (λ) for both the discovery *meta*-analysis and the joint analysis and extended models were less than 1.05, indicating that there was not substantial inflation of the test statistics ([Supplementary Table 3, Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). Association findings from *meta*-analysis and joint analysis were comparable.

In Stage 1, the strongest signal was from the *APOE* region (*e.g.*, rs4420638, *P~M~* =1.1 × 10^−266^, *P~J~* =1.3 × 10^−253^; [Supplementary Table 5](#SD2){ref-type="supplementary-material"}). Excluding the *APOE* region, SNPs at nine distinct loci yielded a *P~M~* or *P~J~* ≤ 10^−6^ ([Table 1](#T1){ref-type="table"}; all SNPs with *P* \< 10^−4^ are in [Supplementary Table 5](#SD2){ref-type="supplementary-material"}). SNPs from these nine loci were carried forward to Stage 2. Five of these had not previously been associated with LOAD at a genome-wide significance level of *P* ≤ 5.0 × 10^−8^ (*MS4A, EPHA1, CD33, ARID5B*, and *CD2AP*). Because Hollingworth *et al.*^[@R12]^ identified SNPs at *ABCA7* as a novel LOAD locus, we included *ABCA7* region SNPs in Stage 2 and provided the results to Hollingworth *et al*.^[@R12]^. For all loci in [Table 1](#T1){ref-type="table"}, we did not detect evidence for effect heterogeneity ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). One novel locus (*MS4A*) was significant in the Stage 1+2 analysis. Four other loci approached but did not reach genome-wide significance in the Stage 1+2 analyses and were carried forward to Stage 3. For three of these (*CD33, EPHA1*, and *CD2AP*), Stage 3 analysis strengthened evidence for association. However, Stages 2 and 3 results did not support Stage 1 results for *ARID5B* 2 ([Table 2](#T2){ref-type="table"}).

Stage 1+2 analysis identified the *MS4A* gene cluster as a novel LOAD locus (*P~M~* = 1.7 × 10^−9^, *P~J~* = 1.7 × 10^−9^)([Table 1](#T1){ref-type="table"}, [Fig. 1A](#F1){ref-type="fig"}). The minor allele (MAF = 0.39) was protective with identical odds ratios (ORs) from both *meta*-analysis and joint analysis (OR~M~ and OR~J~ = 0.88, 95% CI: 0.85--0.92). In the Stage 1+2 analysis, other SNPs gave smaller *P* values when compared to discovery SNP rs4938933, with the most significant SNP being rs4939338 (*P~M~* = 2.6 × 10^−11^, *P~J~* = 4.6 × 10^−11^; *OR*~M~ and *OR*~J~ = 0.87, 95% CI: 0.84--0.91) ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}). In the accompanying manuscript^[@R12]^, genome-wide significant results were also obtained at the *MS4A* locus (rs670139, *P~M~* = 5.0 × 10^−12^) using an independent sample. In a combined analysis of ADGC results and those from Hollingworth *et al*.^[@R12]^, the evidence for this locus at rs4938933 increased to *P~M~* = 8.2 × 10^−12^ (Table 3: OR~M~ = 0.89, 95% CI: 0.87--0.92; [Fig. 1A](#F1){ref-type="fig"}).

SNPs in the *CD2AP* locus also met our Stage 1 criteria for additional analysis ([Fig. 1B](#F1){ref-type="fig"}). Stage 2 data modestly strengthened this association, but the results did not reach genome-wide significance. Stage 3 analysis yielded a genome-wide significance result for rs9349407 (*P~M~* = 8.6 × 10^−9^), identifying *CD2AP* as a novel LOAD locus. The minor allele (MAF = 0.27) at this SNP increased risk for LOAD (*OR~M~* = 1.11, 95% CI: 1.07--1.15) ([Table 2](#T2){ref-type="table"}, [Fig. 1B](#F1){ref-type="fig"}).

Another locus studied further in Stages 2 and 3 centered on *EPHA1*. Previous work provided suggestive evidence that this is a LOAD risk locus, although the associations did not reach genome-wide significance (*P* = 1.7 × 10^−6^)^[@R2]^. Here, results from Stages 1 and 2 for SNP rs11767557, located in the promoter region of *EPHA1*, reached genome-wide significance in the joint analysis. The addition of Stage 3 results increased evidence for association (*P~M~* = 6.0 × 10^−10^, [Table 2](#T2){ref-type="table"}, [Fig. 1C](#F1){ref-type="fig"}). The minor allele (MAF = 0.19) for this SNP is protective (OR~M~ = 0.90, 95% CI: 0.86--0.93). We observed no evidence for heterogeneity at this locus ([Supplementary Fig. 2D](#SD1){ref-type="supplementary-material"}, heterogeneity *P* = 0.58).

In Stages 1 and 2, strong evidence for association was also obtained for SNPs in *CD33*, a gene located approximately 6Mb from *APOE*, but the results did not reach genome-wide significance. The addition of Stage 3 data confirmed that *CD33* is a LOAD risk locus (rs3865444; Stages 1--3, *P~M~* = 1.6 × 10^−9^). The minor allele (MAF = 0.30) is protective (OR~M~ = 0.91, 95% CI: 0.88--0.93; [Tables 1](#T1){ref-type="table"},[2](#T2){ref-type="table"}, [Fig. 1D](#F1){ref-type="fig"}). A single SNP (rs3826656) in the 5' region of *CD33*, was previously reported as an AD-related locus using a family-based approach as genome-wide significant (*P* = 6.6 × 10^−6^) ^[@R15]^. We were unable to replicate this finding (*P~M~* = 0.73; *P~J~* = 0.39, Stage 1 analysis for rs3826656). Though rs3826656 is only 1,348 bp from our top SNP (rs3865444), these 2 sites display only weak LD (*r*^2^ = 0.13).

Hollingworth *et al* ^[@R12]^ report highly significant evidence for the association of an *ABCA7* SNP rs3764650 with LOAD (*P~M~* = 4.5 × 10^−17^) that included data from our study. In our Stage 1+2 analysis, we obtained suggestive evidence for association with *ABCA7* SNP rs3752246 (*P~M~* = 5.8 × 10^−7^, and *P~J~* = 5.0 × 10^−7^), which is a missense variant (G1527A) that may alter the function of the *ABCA7* protein (see [Supplementary Table 6](#SD3){ref-type="supplementary-material"} for functional SNPs in LD with SNPs yielding P~M~ or P~J~ \< 10^−4^).

Our Stage 1+2 analyses also confirmed the association of previously reported loci (*BIN1, CR1, CLU*, and *PICALM*) with LOAD ([Table 1](#T1){ref-type="table"}). For each locus, supporting evidence was *P* ≤ 5.0 × 10^−8^ in one or both types of analysis.

We also examined SNPs with statistically significant GWAS results reported by others (*GAB2*^[@R16]^, *PCDH11X*^[@R17]^, *GOLM1*^[@R18]^, *and MTHFD1L* ^[@R19]^, [Supplementary Table 7](#SD4){ref-type="supplementary-material"}). Stage 1 data were used except for *PCDH11X* where Stage 1+2 data were used because Affymetrix platforms do not contain the appropriate SNP. Only SNPs in the *APOE, CR1, PICALM*, and *BIN1* loci demonstrated *P* \< 10^−6^. For *MTHFD1L*^[@R19]^, at rs11754661 (previously reported *P* = 4.7 × 10^−8^) we obtained modest independent association evidence (OR~M~ = 1.16, 95% CI: 1.04--1.29, *P~M~* = 0.006; OR~J~ = 1.19, 95% CI: 1.08--1.32, *P~J~* = 7.5 × 10^−4^). For the remaining sites, only nominal evidence (*P* \< 0.05) or no evidence was obtained. For the *GAB2* locus^[@R16]^ at rs10793294 (previously reported *P* = 1.60 × 10^−7^), we obtained nominal statistical significance results (*P~M~* = 0.017; *P~J~* = 0.029). The association for rs5984894 in the *PCDH11X* locus^[@R17]^ (previously reported *P* = 3.9 × 10^−12^), did not replicate (*P~M~* = 0.89, *P~J~* = 0.26). Likewise, findings at *GOLM1*^[@R18]^ for rs10868366 (previously reported *P* = 2.40 × 10^−4^) did not replicate (*P~M~* = 0.71; *P~J~* = 0.62). Another gene consistently implicated in LOAD is *SORL1*^[@R20]^ where at rs3781835 (previously reported *P* = 0.006), we obtained modest evidence for association (OR~M~ = 0.72, 95% CI: 0.60--0.86, *P~M~* = 2.9 × 10^−4^; OR~J~ = 0.78, 95% CI: 0.59--0.86; *P~J~* = 3.8 × 10^−4^).

We examined the influence of the *APOE* ε4 allele on the loci in [Table 1](#T1){ref-type="table"}, stratified by and in interactions with *APOE* ε4 allele carrier status. After adjustment, all loci had similar effect sizes to the unadjusted analyses with some showing a modest reduction in statistical significance. We previously reported evidence for a *PICALM-APOE*^[@R21]^ interaction using a dataset that largely overlaps with the Stage 1 dataset used here. However, using the Stage 1+2 data, we do not replicate this finding or see evidence of SNP-*APOE* interactions with [Table 1](#T1){ref-type="table"} loci (data not shown).

Previous work reported an association between LOAD and chromosome 19 SNP rs597668, located 7.2 kb proximal to *EXOC3L2* and 296 kb distal of *APOE* ^[@R2]^. While we did observe a signal for this SNP (Stage 1, *P~M~* = 1.5 × 10^−9^; *P~J~* = 7.7 × 10^−10^) and other SNPs in the *EXOC2L3-MARK4* region, evidence was completely extinguished for all SNPs after adjustment for *APOE* ([Online Methods](#SD5){ref-type="supplementary-material"}, [Supplementary Table 8](#SD1){ref-type="supplementary-material"}), suggesting that signal in this region is from *APOE*.

Our observation of genome-wide significant associations at *MS4A4A, CD2AP, EPHA1*, and *CD33* extend our understanding of the genetic architecture of LOAD and confirm the emerging consensus that common genetic variation plays a significant role in the etiology of LOAD. With our findings and those by Hollingsworth *et al.*^[@R12]^, there are now ten LOAD susceptibility loci (*APOE, CR1, CLU, PICALM, BIN1, EPHA1, MS4A, CD33, CD2AP*, and *ABCA7*). Examining the amount of genetic effect attributable to these candidate genes, the most strongly associated SNPs at each locus other than *APOE* demonstrated population attributable fractions (PAFs) between 2.72--5.97% ([Supplemental Table 9](#SD1){ref-type="supplementary-material"}), with a cumulative PAF for non-*APOE* loci estimated to be as much as 35%; however, these estimates may vary widely between studies^[@R22]^, and the actual effect sizes are likely to be much smaller than those estimated here because of the 'winner's curse'. Also the results do not account for interaction among loci, and are not derived from appropriate population-based samples.

A recent review of GWAS studies^[@R23]^ noted that risk alleles with small effect sizes (0.80 \< OR \< 1.2) likely exist for complex diseases such as LOAD but remain undetected, even with thousands of samples, because of insufficient power^[@R24]^. Our discovery dataset (Stage 1; 8,309 cases and 7,366 controls), was well-powered to detect associations exceeding the statistical significance threshold of *P* \< 10^−6^ ([Supplementary Table 9](#SD1){ref-type="supplementary-material"}). If there are many loci of more modest effects, some, but not all, will likely be detected in any one study. This likely explains the genome-wide statistical significance for the *ABCA7* locus in the accompanying manuscript^[@R12]^, which reaches only modest statistical significance in our dataset (rs3752246; *P~M~* = 1.0 × 10^−5^, *P~J~* = 1.9 × 10^−5^). Finding additional LOAD loci will require larger studies with increased depth of genotyping to test for the effects of both common and rare variants.
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###### Genome-wide Association Results for LOAD in the ADGC Stage 1 and Stage 2 datasets

Association signals represent SNPs with the strongest associations within each locus demonstrating *P* ≤ 10^−6^ in the Stage 1 dataset or in/near previously reported genes, excluding the *APOE* region ([Supplementary Table 5](#SD2){ref-type="supplementary-material"}).

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP          CH:MB     Nearest\                                   MA   MAF    [\#](#TFN5){ref-type="table-fn"}\   ADGC Discovery (Stage 1)   ADGC Replication (Stage 2)   Combined Analysis (Stages 1+2)                                                                                                             
                         Gene                                                   SNPs                                                                                                                                                                                                                                   
  ------------ --------- ------------------------------------------ ---- ------ ----------------------------------- -------------------------- ---------------------------- -------------------------------- ------------- ------------ ------------ ------------ ------------ ------------ ------------- ------------ -------------
  rs6701713    1:207.8   *CR1*[\*](#TFN3){ref-type="table-fn"}      A    0.20   7                                   1.18\                      1.4×10^−8^                   1.19\                            3.5×10^−9^    1.13\        0.004        1.13\        0.004        1.16\        4.6×10^−10^   1.17\        5.2×10^−11^
                                                                                                                    1.11--1.25                                              1.12--1.26                                     1.04--1.23                1.04--1.24                1.11--1.22                 1.12--1.23   

  rs7561528    2:127.9   *BIN1*[\*](#TFN3){ref-type="table-fn"}     A    0.35   10                                  1.18\                      2.9×10^−11^                  1.18\                            7.7×10^−11^   1.15\        1.4×10^−4^   1.15\        1.0×10^−4^   1.17\        4.2×10^−14^   1.17\        5.2×10^−14^
                                                                                                                    1.13--1.24                                              1.12--1.24                                     1.07--1.24                1.07--1.24                1.13--1.22                 1.12--1.22   

  rs9349407    6:47.5    *CD2AP*                                    C    0.27   1                                   1.14\                      1.2×10^−6^                   1.14\                            5.3×10^−6^    1.07\        0.118        1.08\        0.074        1.12\        1.0×10^−6^    1.12\        2.1×10^−6^
                                                                                                                    1.08--1.21                                              1.08--1.20                                     0.98--1.17                0.99--1.18                1.07--1.18                 1.07--1.17   

  rs11767557   7:143.1   *EPHA1*[‡](#TFN4){ref-type="table-fn"}     C    0.19   1                                   0.85\                      7.3×10^−8^                   0.84\                            3.1×10^−8^    0.94\        0.169        0.93\        0.133        0.87\        2.4×10^−7^    0.87\        4.9×10^−8^
                                                                                                                    0.80--0.90                                              0.79--0.89                                     0.86--1.03                0.85--1.02                0.83--0.92                 0.83--0.91   

  rs1532278    8:27.5    *CLU*[\*](#TFN3){ref-type="table-fn"}      T    0.36   2                                   0.90\                      5.6×10^−5^                   0.89\                            2.0×10^−5^    0.87\        2.6×10^−4^   0.87\        2.7×10^−4^   0.89\        8.3×10^−8^    0.89\        1.9×10^−8^
                                                                                                                    0.85--0.95                                              0.85--0.94                                     0.81--0.94                0.81--0.94                0.85--0.93                 0.85--0.92   

  rs2588969    10:63.6   *ARID5B*                                   A    0.37   0                                   0.88\                      1.1×10^−6^                   0.88\                            6.9×10^−7^    1.05\        0.234        1.05\        0.189        0.93\        0.001         0.93\        7.7×10^−4^
                                                                                                                    0.84--0.93                                              0.84--0.93                                     0.97--1.13                0.98--1.13                0.89--0.97                 0.89--0.97   

  rs4938933    11:60.0   *MS4A4A*                                   C    0.39   22                                  0.88\                      5.2×10^−8^                   0.87\                            4.5×10^−8^    0.90\        0.005        0.90\        0.004        0.88\        1.7×10^−9^    0.88\        1.7×10^−9^
                                                                                                                    0.84--0.92                                              0.83--0.92                                     0.84--0.97                0.84--0.97                0.85--0.92                 0.85--0.92   

  rs561655     11:85.8   *PICALM*[\*](#TFN3){ref-type="table-fn"}   G    0.34   36                                  0.88\                      1.2×10^−7^                   0.88\                            4.6×10^−7^    0.86\        8.4×10^−5^   0.86\        3.7×10^−5^   0.87\        7.0×10^−11^   0.87\        1.0×10^−10^
                                                                                                                    0.84--0.92                                              0.84--0.93                                     0.80--0.93                0.80--0.92                0.84--0.91                 0.84--0.91   

  rs3752246    19:1.1    *ABCA7*[%](#TFN6){ref-type="table-fn"}     G    0.19   2                                   1.16\                      1.0×10^−5^                   1.15\                            1.9×10^−5^    1.13\        0.012        1.13\        0.009        1.15\        5.8×10^−7^    1.15\        5.0×10^−7^
                                                                                                                    1.08--1.24                                              1.08--1.23                                     1.03--1.24                1.03--1.25                1.09--1.21                 1.09--1.21   

  rs3865444    19:51.7   *CD33*[\#](#TFN5){ref-type="table-fn"}     A    0.30   1                                   0.88\                      8.2×10^−7^                   0.88\                            1.9×10^−6^    0.91\        0.021        0.92\        0.029        0.89\        1.1×10^−7^    0.89\        2.0×10^−7^
                                                                                                                    0.84--0.93                                              0.84--0.93                                     0.85--0.99                0.85--0.99                0.86--0.93                 0.86--0.93   
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

CH:MB, chromosome:position (in mega base pairs, build 19); MA, minor allele; MAF, minor allele frequency; \# SNPs, the number of SNPs for which *P* ≤ 1 × 10^−6^ in meta-analysis from the combined analysis in Stage 1+2; OR~M~, odds ratio in meta-analysis; *P~M~*, *P*-value in meta-analysis; OR~J~, odds ratio in joint analysis; *P~J~*, *P*-value in joint analysis.

Genes with previous case-control genome-wide statistically significant associations: *CR1^[@R3]^, CLU ^[@R1],[@R3]^, PICALM^[@R1]^, BIN1^[@R2]^*. Gene with a previous association not meeting genome-wide statistical significance: *EPHA1*^[@R2]^. Family-based association study with reported genome-wide statistical significance: *CD33*^[@R15]^.

Genes with previously published case-control association signals at *P* ≤ 5.0 × 10^−8^ are denoted with \*

the case-control locus that did not meet this level of statistical significance is denoted with ^‡^

the locus previously reported in a family-based association study as genome-wide significant with ^\#^

locus identified in Hollingworth *et al.*^[@R12]^ with genome-wide significant evidence for association with. ^%^

###### Meta-Analysis of Stage 1+2 with Stage 3 (CHARGE/GERAD/EADI1 Consortia ^[@R2]^) GWAS Results

Meta-analysis using an external replication case-control sample (Stage 3) for SNPs from novel loci at which associations did not exceed the genome-wide statistical significance threshold (P = 5.0 × 10^−8^) in the ADGC meta-analysis (Stage 1+2). Results for *MS4A* are also included to show association results from the ADGC and accompanying manuscript^[@R12]^. The external replication dataset did not include results from TGEN, ADNI, and MAYO cohorts ([Supplementary Tables 1 and 2](#SD1){ref-type="supplementary-material"}).

  Gene:SNP                  Cases   Controls   Total   OR~M~ (95% CI)      P~M~                OR~j~ (95% CI)      P~J~
  ------------------------- ------- ---------- ------- ------------------- ------------------- ------------------- --------------
  ***CD2AP*: rs9349407**                                                                                           
    ADGC                    11840   10931      22771   1.12 (1.07--1.18)   1.0 × 10^−6^        1.12 (1.07--1.17)   2.1 × 10^−6^
    External                6922    18896      25818   1.09 (1.03--1.15)   0.002               \-                  \-
    ADGC + External         18762   29827      48589   1.11 (1.07--1.15)   **8.6 × 10^−9^**    \-                  \-
                                                                                                                   
  ***EPHA1*: rs11767557**                                                                                          
    ADGC                    11840   10931      22771   0.87 (0.83--0.92)   2.4 × 10^−7^        0.87 (0.83--0.91)   4.9 × 10^−8^
    External                6922    24666      31588   0.91 (0.87--0.96)   2.9 × 10^−4^        \-                  \-
    ADGC + External         18762   35597      54359   0.90 (0.86--0.93)   **6.0 × 10^−10^**   \-                  \-
                                                                                                                   
  ***ARID5B*: rs2588969**                                                                                          
    ADGC                    11840   10931      22771   0.93 (0.89--0.97)   0.001               0.93 (0.89--0.97)   7.8 × 10^−4^
    External                6922    18896      25818   1.06 (1.01--1.11)   0.018               \-                  \-
    ADGC + External         18762   29827      48589   0.99 (0.95--1.02)   0.362               \-                  \-
                                                                                                                   
  ***MS4A4A*: rs4938933**                                                                                          
    ADGC                    11840   10931      22771   0.88 (0.85--0.92)   1.7 × 10^−9^        0.88 (0.85--0.92)   1.7 × 10^−9^
    External                6922    18896      25818   0.92 (0.88--0.97)   5.4 × 10^−4^        \-                  \-
    ADGC + External         18762   29827      48589   0.89 (0.87--0.92)   **8.2 × 10^−12^**   \-                  \-
                                                                                                                   
  ***CD33*: rs3865444**                                                                                            
    ADGC                    11840   10931      22771   0.89 (0.86--0.93)   1.1 × 10^−7^        0.89 (0.86--0.93)   2.0 × 10^−7^
    External                6922    18896      25818   0.92 (0.88--0.97)   0.002               \-                  \-
    ADGC + External         18762   29827      48589   0.91 (0.88--0.93)   **1.6 × 10^−9^**    \-                  \-

[^1]: These authors contributed equally to this work.
